- Home
- KMDA vs NMAI Comparison
KMDA vs NMAI Comparison
Compare KMDA & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- NMAI
- Stock Information
- Founded
- KMDA 1990
- NMAI 2021
- Country
- KMDA Israel
- NMAI United States
- Employees
- KMDA N/A
- NMAI N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- NMAI Investment Managers
- Sector
- KMDA Health Care
- NMAI Finance
- Exchange
- KMDA Nasdaq
- NMAI Nasdaq
- Market Cap
- KMDA 394.4M
- NMAI 399.1M
- IPO Year
- KMDA N/A
- NMAI N/A
- Fundamental
- Price
- KMDA $6.92
- NMAI $12.44
- Analyst Decision
- KMDA Strong Buy
- NMAI
- Analyst Count
- KMDA 2
- NMAI 0
- Target Price
- KMDA $14.50
- NMAI N/A
- AVG Volume (30 Days)
- KMDA 159.8K
- NMAI 74.8K
- Earning Date
- KMDA 03-05-2025
- NMAI 01-01-0001
- Dividend Yield
- KMDA N/A
- NMAI 13.14%
- EPS Growth
- KMDA 124.29
- NMAI N/A
- EPS
- KMDA 0.27
- NMAI 0.64
- Revenue
- KMDA $158,380,000.00
- NMAI N/A
- Revenue This Year
- KMDA $15.37
- NMAI N/A
- Revenue Next Year
- KMDA $8.58
- NMAI N/A
- P/E Ratio
- KMDA $25.36
- NMAI $19.03
- Revenue Growth
- KMDA 4.52
- NMAI N/A
- 52 Week Low
- KMDA $4.74
- NMAI $10.60
- 52 Week High
- KMDA $8.00
- NMAI $12.55
- Technical
- Relative Strength Index (RSI)
- KMDA 50.80
- NMAI 54.99
- Support Level
- KMDA $6.90
- NMAI $12.20
- Resistance Level
- KMDA $7.56
- NMAI $12.49
- Average True Range (ATR)
- KMDA 0.19
- NMAI 0.09
- MACD
- KMDA -0.09
- NMAI 0.04
- Stochastic Oscillator
- KMDA 15.95
- NMAI 73.84
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.